Cancer — the mitochondrial connection

Mitochondria are the powerhouse of the cell. They play a vital role in the energy metabolism and regulate calcium flux and apoptosis. The recent resurgence of interest in mitochondrial studies is largely attributed to the recognition that mitochondrial dysfunctions lead to various physiopathological disorders, especially in the development and progression of cancer. Mitochondrial DNA is very susceptible to mutations, which lead to respiratory dysfunction and are implicated in many cancers. Mitochondria serve as the molecular target for a structurally diverse group of pharmacological agents in cancer chemotherapy. Biochemical and biophysical characterization have helped to identify several important differences between mitochondria of normal and disease state. Such unique alterations in mitochondrial structure and function could become promising target for the development of new generation drugs.

[1]  M. Caligiuri,et al.  Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. , 2003, Blood.

[2]  G Parmigiani,et al.  Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. , 2001, Cancer research.

[3]  Howard Y. Chang,et al.  Proteases for Cell Suicide: Functions and Regulation of Caspases , 2000, Microbiology and Molecular Biology Reviews.

[4]  V. Torchilin,et al.  Cationic bolasomes with delocalized charge centers as mitochondria-specific DNA delivery systems. , 2001, Advanced drug delivery reviews.

[5]  R. L. Cross.  Our primary source of ATP , 1994, Nature.

[6]  G. Cohen,et al.  Apoptotic death sensor: an organelle's alter ego? , 2001, Trends in pharmacological sciences.

[7]  M. Duchen.  Mitochondria in health and disease: perspectives on a new mitochondrial biology. , 2004, Molecular aspects of medicine.

[8]  A. Cheung,et al.  High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. , 2001, Cancer research.

[9]  S. Martin,et al.  The mitochondrial apoptosome: a killer unleashed by the cytochrome seas. , 2001, Trends in biochemical sciences.

[10]  A. Degterev,et al.  The channel of death , 2001, The Journal of cell biology.

[11]  L. Kirshenbaum,et al.  Mitochondria-assisted cell suicide: a license to kill. , 2003, Journal of molecular and cellular cardiology.

[12]  D. Shibata,et al.  Somatic mitochondrial mutation in gastric cancer. , 1995, The American journal of pathology.

[13]  D. Wallace,et al.  Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. , 1988, Science.

[14]  B. Van Houten,et al.  Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Shishido,et al.  MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. , 1996, Cancer research.

[16]  A. Nakao,et al.  Mitochondrial DNA alteration in esophageal cancer , 2001, International journal of cancer.

[17]  X. Wang.  The expanding role of mitochondria in apoptosis. , 2001, Genes & development.

[18]  J. Martinou,et al.  Mitochondria as the central control point of apoptosis. , 2000, Trends in cell biology.

[19]  A. Oseroff,et al.  GRP78 Induction by Calcium lonophore Potentiates Photodynamic Therapy Using the Mitochondrial Targeting Dye Victoria Blue BO , 1998, Photochemistry and photobiology.

[20]  M. Boeseman.  Fresh-water Sawfishes and Sharks in Netherlands New Guinea. , 1956, Science.

[21]  D. Green,et al.  A Matter of Life and Death , 2008, Science.

[22]  I. Summerhayes,et al.  Selective toxicity of rhodamine 123 in carcinoma cells in vitro. , 1983, Cancer research.

[23]  J. Modica-Napolitano,et al.  Mitochondria as targets for detection and treatment of cancer , 2002, Expert Reviews in Molecular Medicine.

[24]  B. Zhivotovsky,et al.  Distinct Pathways for Stimulation of Cytochrome cRelease by Etoposide* , 2000, The Journal of Biological Chemistry.

[25]  L. Hays,et al.  Mitochondrial DNA copy number changes in human gliomas. , 1996, Cancer letters.

[26]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[27]  V. Bohr,et al.  Repair of alkali-labile sites within the mitochondrial DNA of RINr 38 cells after exposure to the nitrosourea streptozotocin. , 1991, The Journal of biological chemistry.

[28]  J Salvage,et al.  A matter of life and death. , 1981, Nursing times.

[29]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[30]  N. Hail.  Mitochondria: A novel target for the chemoprevention of cancer , 2005, Apoptosis.

[31]  C. Myers,et al.  Hydroxyl radical production and DNA damage induced by anthracycline‐iron complex , 1984, FEBS letters.

[32]  D. A. Clayton,et al.  Circular Dimer and Catenate Forms of Mitochondrial DNA in Human Leukaemic Leucocytes , 1967, Nature.

[33]  H. Schmidt,et al.  Renal toxicity of the neuron-blocking and mitochondriotropic agent m-iodobenzylguanidine , 1998, Cancer Chemotherapy and Pharmacology.

[34]  S. Nishizuka,et al.  Mutations in mitochondrial control region DNA in gastric tumours of Japanese patients. , 1999, European journal of cancer.

[35]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[36]  A. Alonso,et al.  Detection of somatic mutations in the mitochondrial DNA control region of colorectal and gastric tumors by heteroduplex and single‐strand conformation analysis , 1997, Electrophoresis.

[37]  J. T. Wachsman,et al.  Mitochondrial DNA in human malignancy. , 2001, Mutation research.

[38]  R. Salem,et al.  Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  V. Skulachev,et al.  Mechanism of Coupling of Oxidative Phosphorylation and the Membrane Potential of Mitochondria , 1969, Nature.

[40]  C. Guguen-Guillouzo,et al.  Increased level of the mitochondrial ND5 transcript in chemically induced rat hepatomas. , 1989, Experimental cell research.

[41]  Bert Vogelstein,et al.  Somatic mutations of the mitochondrial genome in human colorectal tumours , 1998, Nature Genetics.

[42]  S. Nomoto,et al.  Mitochondrial mutations in early stage prostate cancer and bodily fluids , 2001, Oncogene.

[43]  S. Cory,et al.  Apoptosomes: engines for caspase activation. , 2002, Current opinion in cell biology.

[44]  A. Harding,et al.  Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies , 1988, Nature.

[45]  D. Wallace,et al.  Novel mitochondrial DNA deletion found in a renal cell carcinoma , 1996, Genes, chromosomes & cancer.

[46]  Luca Scorrano,et al.  A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. , 2002, Cancer cell.

[47]  B. Lemire,et al.  The role of mitochondria in the life of the nematode, Caenorhabditis elegans. , 2003, Biochimica et biophysica acta.

[48]  T. Cotter,et al.  Regulation and measurement of oxidative stress in apoptosis. , 2002, Journal of immunological methods.

[49]  Marty C. Brandon,et al.  Mitochondrial mutations in cancer , 2006, Oncogene.

[50]  Mukesh Verma,et al.  Proteomic analysis of cancer-cell mitochondria , 2003, Nature Reviews Cancer.

[51]  D. Green,et al.  Apoptosis: checkpoint at the mitochondrial frontier. , 1999, Mutation research.

[52]  Volkmar Weissig,et al.  Liposomes and Liposome-like Vesicles for Drug and DNA Delivery to Mitochondria , 2006, Journal of liposome research.

[53]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[54]  L. Boise,et al.  Mitochondria as targets for established and novel anti-cancer agents. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[55]  Keshav K. Singh,et al.  Mitochondrial DNA determines the cellular response to cancer therapeutic agents , 1999, Oncogene.

[56]  A. Szewczyk,et al.  Mitochondria as a Pharmacological Target , 2002, Pharmacological Reviews.

[57]  R. Seruca,et al.  Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma , 2001, Genes, chromosomes & cancer.

[58]  K. Lunetta,et al.  Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours , 2000, Oncogene.

[59]  D. Wallace,et al.  Mitochondrial DNA in aging and disease. , 1997, Scientific American.

[60]  Michael E Phelps,et al.  Positron emission tomography scanning: current and future applications. , 2002, Annual review of medicine.

[61]  Emad S. Alnemri,et al.  Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1 , 1999, Nature.

[62]  E Gabrielson,et al.  Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. , 2001, Cancer research.

[63]  D. Rideout,et al.  Mechanism of inhibition of fadu hypopharyngeal carcinoma cell growth by tetraphenylphosphonium chloride , 1994, International journal of cancer.

[64]  G. Kroemer,et al.  Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore , 1999, Oncogene.

[65]  G. Indig,et al.  Effect of dye aggregation on triarylmethane-mediated photoinduced damage of hexokinase and DNA. , 2002, Journal of photochemistry and photobiology. B, Biology.

[66]  P. Cerutti.  Prooxidant states and tumor promotion. , 1985, Science.

[67]  J. Jen,et al.  Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. , 2000, Science.

[68]  A. Oseroff,et al.  Intramitochondrial dyes allow selective in vitro photolysis of carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[69]  H. Yoshida,et al.  [Machinery of programmed cell death]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[70]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[71]  R. Seruca,et al.  Comments on: mutations in mitochondrial control region DNA in gastric tumours of Japanese patients, Tamura, et al. Eur J Cancer 1999, 35, 316-319. , 1999, European journal of cancer.

[72]  L. Ernster,et al.  A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. , 1962, The Journal of clinical investigation.

[73]  M. M. Nass,et al.  INTRAMITOCHONDRIAL FIBERS WITH DNA CHARACTERISTICS: I. Fixation and Electron Staining Reactions , 1963 .

[74]  T. Lampidis,et al.  Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. , 1983, Science.

[75]  Y. Tsujimoto,et al.  VDAC regulation by the Bcl-2 family of proteins , 2000, Cell Death and Differentiation.

[76]  Lee-Jun C Wong,et al.  Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. , 2002, Cancer research.

[77]  Chi V Dang,et al.  Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.

[78]  J. Modica-Napolitano,et al.  Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077. , 1996, Cancer research.

[79]  L. B. Chen,et al.  AA1, a newly synthesized monovalent lipophilic cation, expresses potent in vivo antitumor activity. , 1994, Cancer research.

[80]  Š. Kǔzela,et al.  Increased steady-state levels of several mitochondrial and nuclear gene transcripts in rat hepatoma with a low content of mitochondria. , 1992, European journal of biochemistry.

[81]  Peng Huang,et al.  Mitochondrial defects in cancer , 2002, Molecular Cancer.

[82]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.